MDMA-assisted therapy for young adults with chronic treatment-resistant major depressive disorder

Phase 2, randomised, open-label trial of midomafetamine in major depressive disorder (MDD) (2 arms), sponsored by Ostfold Hospital Trust. Primary endpoints: Recruitment and retention and Moderate to severe adverse events, adverse events of special interest, and serious adverse events. Planned start Jul 2026; status: authorised.